Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Humacyte Q2 revenue rises to $0.4 million as net loss narrows

None

Humacyte (HUMA) reported second-quarter 2026 revenue of $0.4 million, up from $0.3 million a year earlier, and a net loss of $36.8 million, compared with a net loss of $37.7 million in the second quarter of 2025.

The company said Symvess commercial sales were $0.4 million in the quarter, compared with $0.1 million a year earlier. Humacyte also reported Phase 3 dialysis access results for ATEV, plans to file a supplemental BLA in the second half of 2026, and said the FDA accepted its IND for a first-in-human CTEV study in CABG.

  • Second-quarter 2026 total revenue was $406,000.
  • Net loss was $36.8 million, or $0.16 per basic and diluted share.
  • Six-month 2026 revenue was $0.9 million, compared with $0.8 million a year earlier.
  • Cash, cash equivalents and restricted cash totaled $80.3 million as of June 30, 2026.
  • Humacyte raised $57.5 million in gross proceeds from a June 2026 public offering.
  • The company estimated 2026 net savings of about $14.3 million from workforce and operating cost reductions.

$HUMAW Hedge Fund Activity

We have seen 2 institutional investors add shares of $HUMAW stock to their portfolio, and 4 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles